Harvard Law School's Forum on Corporate Governance released its annual proxy season analysis this week, isolating two inflection points for 2026: shareholder campaigns increasingly center on M&A preparedness and artificial intelligence governance gaps. The paper tracks 127 activist engagements across Russell 3000 constituents from January through October, a 19% uptick year-over-year, with poison pill structures and AI risk committees appearing in 34 proxy contests—double the prior season's count.
The shift is architectural. Activists no longer wait for a rumored bid to surface. They preemptively push boards to adopt formal M&A review frameworks, argue for independent transaction committees, and demand quarterly portfolio strategy disclosures. Elliot Management, Starboard Value, and TCI Fund Management each filed at least three such resolutions this cycle. The paper notes that 41% of those campaigns secured board seats or negotiated standstill agreements before the vote, compared to 28% in 2025. Boards resistant to structured deal evaluation now face a credible threat of shareholder rebellion before any offer arrives.
AI oversight emerged as the second-order surprise. Institutional allocators—led by CalPERS, the New York State Common Retirement Fund, and Vanguard's stewardship team—filed 22 proposals requiring independent AI ethics committees or mandating quarterly disclosures on algorithmic risk. Only 31% of those proposals passed, but that is immaterial. The paper highlights that 14 boards voluntarily adopted AI governance charters within sixty days of the filing deadline, preempting the vote. What matters is not the tally but the normalization of the ask. Boards treating AI as an IT question rather than a fiduciary question are now on notice.
The paper's methodology is worth understanding. Harvard's team analyzed proxy filings, settlement agreements, and investor letters across three years, cross-referenced against deal announcements and board composition changes. They isolated campaigns that explicitly mentioned M&A readiness or AI risk in their public rationale, then tracked outcomes through AGM votes and subsequent regulatory disclosures. The sample excludes microcap names and special-purpose acquisition vehicles, focusing on operating companies with market caps above $500 million. This is not sentiment analysis. This is a structural read on where capital allocation arguments are heading.
What operators and allocators should watch: poison pill adoptions in Q1 2027 among healthcare and industrial firms, particularly those with enterprise values between $2 billion and $8 billion—the zone where activists have secured the highest win rates. Also monitor the formation of technology oversight subcommittees at financial services boards; the paper flags that sector as the next frontier for AI governance campaigns. Expect Institutional Shareholder Services and Glass Lewis to update their proxy voting guidelines on both topics by March 2027, which will formalize what is currently discretionary.
The proxy season is no longer a calendar event. It is a twelve-month negotiation cycle with two new permanent agenda items.